To Boost Or Not To Boost? Pfizer, FDA, And The COVID Vaccine Communication Challenge
Executive Summary
Pfizer’s bid for third dose appears to get pushback from the US government, but reticence about the booster may reflect PR considerations more than any fundamental concern about the vaccine.
You may also be interested in...
US FDA’s Top Two Vaccine Officials Announce Surprise Retirements
Departures of Marion Gruber and Philip Krause may stem from White House and CDC actions related to the COVID-19 vaccines.
Don’t Call It A Booster: Immunocompromised May Be First To Get Extra COVID Shot In US
Reports indicate a 13 August CDC advisory committee meeting may be used to address an amended FDA emergency use authorization to allow immunosuppressed Americans to get additional COVID-19 vaccine doses. Such a move would not run afoul of the World Health Organization’s plea for a moratorium on boosters in the general population until much of the world initially can be vaccinated.
Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business
The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.